Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management."
- Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management."
- This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
- Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life.
- Companies featured in the report include ConnectBiopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), MirumPharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR).